Wedbush analyst Laura Chico downgraded Chinook Therapeutics to Neutral from Outperform with a $42 price target.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KDNY:
- Chinook Therapeutics downgraded to Equal Weight from Overweight at Wells Fargo
- Chinook Therapeutics Announces First Patient Enrolled in Pivotal Phase 3 BEYOND Study of Zigakibart (BION-1301) for Patients with IgA Nephropathy
- Chinook announces first patient enrolled in Phase 3 BEYOND study of BION-1301
- Chinook Therapeutics presents data from CHK-336 Phase 1 trial
- Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress